BRPI1008920A2 - Composição farmacêutica para liberação de compostos inibidores de receptor de tirosina quinase (rtki) para o olho - Google Patents

Composição farmacêutica para liberação de compostos inibidores de receptor de tirosina quinase (rtki) para o olho

Info

Publication number
BRPI1008920A2
BRPI1008920A2 BRPI1008920-9A BRPI1008920A BRPI1008920A2 BR PI1008920 A2 BRPI1008920 A2 BR PI1008920A2 BR PI1008920 A BRPI1008920 A BR PI1008920A BR PI1008920 A2 BRPI1008920 A2 BR PI1008920A2
Authority
BR
Brazil
Prior art keywords
rtki
eye
release
pharmaceutical composition
tyrosine kinase
Prior art date
Application number
BRPI1008920-9A
Other languages
English (en)
Portuguese (pt)
Inventor
Bhagwati P Kabra
Original Assignee
Alcon Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Res Ltd filed Critical Alcon Res Ltd
Publication of BRPI1008920A2 publication Critical patent/BRPI1008920A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI1008920-9A 2009-03-03 2010-03-03 Composição farmacêutica para liberação de compostos inibidores de receptor de tirosina quinase (rtki) para o olho BRPI1008920A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15698409P 2009-03-03 2009-03-03
PCT/US2010/025998 WO2010101971A1 (en) 2009-03-03 2010-03-03 Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye

Publications (1)

Publication Number Publication Date
BRPI1008920A2 true BRPI1008920A2 (pt) 2015-08-25

Family

ID=42678477

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1008920-9A BRPI1008920A2 (pt) 2009-03-03 2010-03-03 Composição farmacêutica para liberação de compostos inibidores de receptor de tirosina quinase (rtki) para o olho

Country Status (11)

Country Link
US (1) US20100226992A1 (enExample)
EP (1) EP2403342A4 (enExample)
JP (1) JP5583145B2 (enExample)
KR (1) KR20110123789A (enExample)
CN (2) CN102340993A (enExample)
AU (1) AU2010221438C1 (enExample)
BR (1) BRPI1008920A2 (enExample)
CA (1) CA2753837A1 (enExample)
MX (1) MX2011008680A (enExample)
WO (1) WO2010101971A1 (enExample)
ZA (1) ZA201105506B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3252079B8 (en) 2006-04-07 2020-09-09 Aerpio Therapeutics LLC Antibodies that bind human protein tyrosine phosphatase beta (hptp-beta) and uses thereof
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
TW201023912A (en) 2008-12-05 2010-07-01 Alcon Res Ltd Pharmaceutical suspension
WO2010101989A1 (en) 2009-03-03 2010-09-10 Alcon Research, Ltd. PHARMACEUTICAL COMPOSITION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
PL2451279T3 (pl) 2009-07-06 2019-09-30 Aerpio Therapeutics, Inc. Pochodne benzosulfonamidowe, ich kompozycje i ich zastosowanie w zapobieganiu przerzutom komórek nowotworowych
AU2012323856B2 (en) 2011-10-13 2017-05-25 EyePoint Pharmaceuticals, Inc. Methods for treating Vascular Leak Syndrome and cancer
TW201330850A (zh) * 2011-12-14 2013-08-01 Abbvie Inc 包含激酶抑制劑之組合物
EP2825166A1 (en) * 2012-03-12 2015-01-21 Allergan, Inc. Method of treating ophthalmic conditions with kinase inhibitors
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
TW201518291A (zh) 2013-09-20 2015-05-16 參天製藥股份有限公司 含聚乙二醇之組成物
US9994560B2 (en) 2014-03-14 2018-06-12 Aerpio Therapeutics, Inc. HPTP-β inhibitors
MA56220A (fr) * 2014-09-17 2022-04-20 Panoptica Inc Formulations oculaires permettant l'administration de médicament et la protection du segment antérieur de l'oeil
EP3302061A4 (en) * 2015-06-05 2019-02-27 Kato Pharmaceuticals, Inc. UREA COMPOSITIONS WITH EXTENDED RELEASE
TWI700085B (zh) * 2015-06-22 2020-08-01 新源生物科技股份有限公司 酪胺酸激酶抑制劑之眼用調配物的用途
CN113713101B (zh) 2015-09-23 2023-07-28 视点制药公司 用tie-2的激活剂治疗眼内压的方法
WO2020223209A1 (en) 2019-04-29 2020-11-05 Aerpio Pharmaceuticals, Inc. Tie-2 activators targeting the schlemm's canal
WO2021051003A1 (en) * 2019-09-13 2021-03-18 Aldeyra Therapeutics, Inc. Ophthalmic formulations of methotrexate
US12337012B2 (en) 2019-09-27 2025-06-24 Virginia Commonwealth University Compositions and methods for restoring or increasing tissue perfusion
CN116251186B (zh) * 2021-12-09 2025-04-25 成都瑞沐生物医药科技有限公司 一种酪氨酸激酶抑制剂眼用制剂及其制备方法和用途

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3856919A (en) * 1970-06-08 1974-12-24 Burton Parsons Chemicals Inc Ophthalmic solution
US3931319A (en) * 1974-10-29 1976-01-06 Millmaster Onyx Corporation Capped polymers
US4027020A (en) * 1974-10-29 1977-05-31 Millmaster Onyx Corporation Randomly terminated capped polymers
US4409205A (en) * 1979-03-05 1983-10-11 Cooper Laboratories, Inc. Ophthalmic solution
US4525346A (en) * 1981-09-28 1985-06-25 Alcon Laboratories, Inc. Aqueous antimicrobial ophthalmic solutions
US4407791A (en) * 1981-09-28 1983-10-04 Alcon Laboratories, Inc. Ophthalmic solutions
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4836986A (en) * 1984-09-28 1989-06-06 Bausch & Lomb Incorporated Disinfecting and preserving systems and methods of use
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5037647A (en) * 1988-09-15 1991-08-06 Alcon Laboratories, Inc. Aqueous antimicrobial opthalmic solutions comprised of quaternary ammonium compound, citric acid, citrate and sodium chloride
US5461081A (en) * 1989-09-28 1995-10-24 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
US5932572A (en) * 1992-02-21 1999-08-03 Alcon Laboratories, Inc. Topical anti-glaucoma compositions
US5300287A (en) * 1992-11-04 1994-04-05 Alcon Laboratories, Inc. Polymeric antimicrobials and their use in pharmaceutical compositions
CA2153234C (en) * 1993-04-16 1999-02-16 Masanobu Takeuchi Aqueous drug composition having property of reversible thermosetting gelation
EP0842663A4 (en) * 1996-05-07 2003-06-18 Toray Industries OPHTHALMIC PREPARATIONS
PT970175E (pt) * 1997-07-29 2003-02-28 Alcon Lab Inc Solucoes de acondicionamento para cuidar de lentes de contacto rigidas
AU6870800A (en) * 1999-09-06 2001-04-10 Ono Pharmaceutical Co. Ltd. Preventive and therapeutic agents for eye diseases
PL201130B1 (pl) * 1999-09-24 2009-03-31 Alcon Inc Kompozycje zawiesinowe zawierające ciprofloksacynę i deksametazon do podawania miejscowego do oczu, uszu lub nosa
AU4511201A (en) * 1999-12-03 2001-06-12 Ista Pharmaceuticals, Inc Compositions and methods for the induction and treatment of retinal detachments
WO2001087262A2 (en) * 2000-05-15 2001-11-22 Pharmacia Italia S.P.A. Stabilized steroidal suspension
US20020037877A1 (en) * 2000-07-26 2002-03-28 Alcon Universal Ltd. Pharmaceutical suspension compositions lacking a polymeric suspending agent
JP3450805B2 (ja) * 2000-08-08 2003-09-29 わかもと製薬株式会社 水性医薬組成物
US20040256749A1 (en) * 2000-12-22 2004-12-23 Mahesh Chaubal Process for production of essentially solvent-free small particles
US6743439B1 (en) * 2001-06-27 2004-06-01 Alcon, Inc. Ophthalmic compositions containing copolymers of sulfonated styrene and maleic anhydride
DK1429780T3 (da) * 2001-09-21 2006-02-13 Fremgangsmåde til behandling af mellemoreinfektioner
US7001615B1 (en) * 2001-12-07 2006-02-21 Alcon, Inc. Sustained release ophthalmic, otic and nasal suspension
MXPA05000232A (es) * 2002-06-21 2005-06-17 Transform Pharmaceuticals Inc Composiciones farmaceuticas con disolucion mejorada.
US20040235892A1 (en) * 2003-05-22 2004-11-25 Yujia Dai Indazole and benzisoxazole kinase inhibitors
JP4810427B2 (ja) * 2003-05-22 2011-11-09 アボット・ラボラトリーズ インダゾール、ベンズイソオキサゾールおよびベンズイソチアゾールキナーゼ阻害剤
CA2562356A1 (en) * 2004-04-08 2005-10-27 Retmed Pty Ltd Treatment of ophthalmic conditions with mineralcorticoids
TWI358290B (en) * 2004-12-02 2012-02-21 Alcon Inc Topical nepafenac formulations
TW200640443A (en) * 2005-02-23 2006-12-01 Alcon Inc Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
WO2006121964A2 (en) * 2005-05-10 2006-11-16 Alcon, Inc. Ophthalmic suspension comprising an ophthalmic drug, a poloxamine and a glycol tonicity-adjusting agent, use of said composition for the manufacture of a medicament for treating ophthalmic disorders
PT1885336E (pt) * 2005-05-10 2009-05-07 Alcon Inc Formulações de suspensão compreendendo um princípio activo, um tensoactivo poloxâmero ou meroxapol e um glicol, sua utilização no fabrico de um medicamento para tratamento de distúrbios oftálmicos
US20070149480A1 (en) * 2005-12-23 2007-06-28 Alcon, Inc. PHARMACEUTICAL COMPOSITION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
US20070149593A1 (en) * 2005-12-23 2007-06-28 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
US20070173538A1 (en) * 2005-12-23 2007-07-26 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
US20070249546A1 (en) * 2006-04-22 2007-10-25 Sawaya Assad S Ophthalmic and related aqueous solutions containing antifungal agents, uses therefor and methods for preparing them
BRPI0721885A2 (pt) * 2007-07-20 2014-02-25 Alcon Inc Formulação farmacêutica para distribuição de compostos inibidores de receptores de tirosina quinase (rtki) para os olhos
TW201023912A (en) * 2008-12-05 2010-07-01 Alcon Res Ltd Pharmaceutical suspension

Also Published As

Publication number Publication date
US20100226992A1 (en) 2010-09-09
AU2010221438C1 (en) 2015-01-29
ZA201105506B (en) 2012-09-26
MX2011008680A (es) 2011-09-08
CA2753837A1 (en) 2010-09-10
JP2012519692A (ja) 2012-08-30
EP2403342A1 (en) 2012-01-11
JP5583145B2 (ja) 2014-09-03
EP2403342A4 (en) 2013-06-05
CN105362221A (zh) 2016-03-02
AU2010221438B2 (en) 2014-10-16
CN102340993A (zh) 2012-02-01
AU2010221438A1 (en) 2011-08-25
KR20110123789A (ko) 2011-11-15
WO2010101971A1 (en) 2010-09-10

Similar Documents

Publication Publication Date Title
BRPI1008920A2 (pt) Composição farmacêutica para liberação de compostos inibidores de receptor de tirosina quinase (rtki) para o olho
BRPI1012302A2 (pt) composição farmacêutica para a liberação de compostos de inibição de tirosina quinase receptora (rtki) para o olho
BRPI0919466A2 (pt) composição farmacêutica para liberação modificada
EP2376495A4 (en) COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS
BRPI0912362A2 (pt) antagonista do receptor nmda para o tratamento de transtornos neuropsiquiátricos
BRPI0911988A2 (pt) micelas para liberação intracelular de agentes terapêuticos.
PT2435030E (pt) Composições farmacêuticas flutuantes de libertação controlada
BR112012004525A2 (pt) composição farmacêuticas gástrico-rententivas para liberação imediata ou prolongada de acetaminofeno
BRPI0913235A2 (pt) forma de dosagem farmacêutica para liberação imediata de um derivado de indolinona
EP2694060A4 (en) SUBSTITUTED 3- (1H-BENZO- {D} -IMIDAZOL-2-YL-) 1H-INDAZOL ANALOGUE AS PDK1 KINASE INHIBITOR
BRPI0918971A2 (pt) tienopirimidinas para composições farmacêuticas
DK3354650T3 (da) Forbindelser der er nyttige som inhibitorer af ATR-kinase
EP2142287A4 (en) INHIBITORS OF LYSINPECIFIC DEMETHYLASE
EP2515657A4 (en) Tyrosine kinase inhibitor
EA201101118A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
EP2930167A4 (en) TINOSOLINE INHIBITOR USED AS COMPLETE INDOLKETONE DERIVATIVE
BRPI0912428A2 (pt) formulação farmacêutica sólida de liberação retardada
BRPI1011412A2 (pt) composição para liberação sustentada de droga compreendendo alutinante geopolimérico
EP2231152A4 (en) THIENOPYRANONE AS A KINASEHEMMER
BRPI0812250A2 (pt) Composição farmacêutica de liberação lenta feita de micropartículas
CL2014002986A1 (es) Proceso para la preparacion de compuestos derivados de 2-(1-hidroxi-alquil)-cromen-4-ona opticamente puros y opcionalmente sustituidos; compuestos derivados de 2-(1-hidroxi-alquil)-cromen-4-ona; composicion farmaceutica que los comprende; y su uso para preparar compuestos inhibidores de pi3k.
BRPI0909270A2 (pt) Compostos de sirna para inibição de rtp801
TN2009000510A1 (en) Extended release formulation of nevirapine
DK2462098T3 (da) Fremgangsmåde til fremstillingen af derivater af 1-(2-halobiphenyl-4-yl)-cyclopropancarboxylsyre
HRP20150752T1 (xx) Piridinil- i pirazinilmetoksiarilni derivati, korisni kao inhibitori slezenske tirozinske kinaze

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]